MAYLIN ALMONTE ALMONTE-BECERRIL

Dr. MAYLIN ALMONTE ALMONTE-BECERRIL


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
LALorena Albarracín-Navas
Lorena Albarracín-Navas
MAMAYLIN ALMONTE ALMONTE-BECERRIL
MAYLIN ALMONTE ALMONTE-BECERRIL
EGEnmanuel Guerrero
Enmanuel Guerrero
JRJosue Rivadeneira
Josue Rivadeneira
MTMARCELINO TELECHEA
MARCELINO TELECHEA
ARAngela L. Riffo-Campos
Angela L. Riffo-Campos
Background: Prostate cancer is the second most common neoplasm in men, with projections estimating over one million new cases by 2045. Differentially expressed genes can significantly enhance the diagnosis, treatment, monitoring, and prognosis of this disease. Purpose: to systematically review and analyze validated differentially expressed mRNAs in prostate cancer patients to propose a robust molecular profile for clinical diagnostics. Methods: A systematic review was conducted following PRISMA guidelines, searching literature databases for mRNAs with validated differential expression in adult prostate cancer patients. Identified mRNAs were analyzed using STRING, Cytoscape, and DrugBank to explore protein–protein interactions and potential drug targets. Results: A total of 5003 participants from Europe, Asia, America, and Oceania were included, and 144 mRNAs (p < 0.05) were reported across 75 primary articles, predominantly validated using RT-qPCR with tissue samples. Among these, at least 36 mRNAs were identified as targets for cancer-related drugs. Enrichment analysis revealed the top pathways were associated with cancer, including specific prostate cancer terms. Key nodes emerged as hubs in the protein–protein interaction network. Conclusion: Based on our comprehensive in silico analysis of validated differentially expressed mRNAs, we propose a molecular profile of twenty-five mRNAs with significant potential for clinical diagnosis of prostate cancer. These findings offer a valuable foundation for developing precision oncology strategies to improve patient outcomes.

5 December 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
LALorena Carlota Albarracin
Lorena Carlota Albarracin
NSNicolás Ignacio Lara Salas
Nicolás Ignacio Lara Salas
JRJavier Alarcón Roa
Javier Alarcón Roa
MAMAYLIN ALMONTE ALMONTE-BECERRIL
MAYLIN ALMONTE ALMONTE-BECERRIL
EGEnmanuel Guerrero
Enmanuel Guerrero
ARAngela L. Riffo-Campos
Angela L. Riffo-Campos
Background: Non-coding RNAs (ncRNAs) have emerged as promising biomarkers for prostate cancer (PCa), yet evidence remains dispersed across heterogeneous studies and their regulatory context is seldom analyzed in an integrated manner. This study systematically maps ncRNAs reported as diagnostic biomarkers for PCa and characterizes their molecular interactions through in silico analyses. Methods: A comprehensive evidence-mapping strategy across major bibliographic databases identified 693 studies, of which 58 met eligibility criteria. Differentially expressed ncRNAs were extracted and classified by RNA type. Subsequently, miRNA–target prediction, miRNA–protein interaction network construction, and functional enrichment analyses were performed to explore the regulatory landscape of miRNA-associated proteins. Results: The final dataset included 4,500 participants (2,871 PCa cases and 2,093 controls) and reported 94 differentially expressed miRNAs, eight lncRNAs, and several circRNAs, snoRNAs, snRNAs, and piRNAs. In silico analyses predicted 13,493 miRNA–mRNA interactions converging on 4,916 unique target genes, with an additional 2,481 prostate tissue–specific targets. The miRNA–protein network comprised 845 nodes and 2,335 edges, revealing highly connected miRNAs (e.g., hsa-miR-16-5p, hsa-miR-20a-5p) and protein hubs (QKI, YOD1, TBL1XR1; prostate-specific CDK6, ACVR2B). Enrichment analysis showed strong overrepresentation of metabolic process–related GO terms and cancer-associated KEGG pathways. Conclusions: These findings refine the list of promising ncRNA biomarkers and highlight candidates for future clinical validation.

8 January 2026 in Life
Verified
Journal Article
Open access
PDF file
LALorena Carlota Albarracin
Lorena Carlota Albarracin
NSNicolás Ignacio Lara Salas
Nicolás Ignacio Lara Salas
JAJavier H. Alarcon-Roa
Javier H. Alarcon-Roa
MAMAYLIN ALMONTE ALMONTE-BECERRIL
MAYLIN ALMONTE ALMONTE-BECERRIL
EGEnmanuel Guerrero
Enmanuel Guerrero
ARAngela L. Riffo-Campos
Angela L. Riffo-Campos
Non-coding RNAs (ncRNAs) have emerged as promising biomarkers for prostate cancer (PCa), yet evidence remains dispersed across heterogeneous studies and their regulatory context is seldom analyzed in an integrated manner. This study systematically maps ncRNAs reported as diagnostic biomarkers for PCa and characterizes their molecular interactions through in silico analyses. A comprehensive evidence-mapping strategy across major bibliographic databases identified 693 studies, of which 58 met eligibility criteria. Differentially expressed ncRNAs were extracted and classified by RNA type. Subsequently, miRNA–target prediction, miRNA–protein interaction network construction, and functional enrichment analyses were performed to explore the regulatory landscape of miRNA-associated proteins. Results: The final dataset included 4500 participants (2871 PCa cases and 2093 controls) and reported 94 differentially expressed miRNAs, eight lncRNAs, and several circRNAs, snoRNAs, snRNAs, and piRNAs. In silico analyses predicted 13,493 miRNA–mRNA interactions converging on 4916 unique target genes, with an additional 2481 prostate tissue-specific targets. The miRNA–protein network comprised 845 nodes and 2335 edges, revealing highly connected miRNAs (e.g., hsa-miR-16-5p, hsa-miR-20a-5p) and protein hubs (QKI, YOD1, TBL1XR1; prostate-specific CDK6, ACVR2B). Enrichment analysis showed strong overrepresentation of metabolic process-related GO terms and cancer-associated KEGG pathways. Conclusions: These findings refine the list of promising ncRNA biomarkers and highlight candidates for future clinical validation.